Ramsay Health Care shares ward off pain from credit rating cut

The private hospital operator has taken a hit to its investment grade credit rating.

| More on:
Stressed thoughtful old female general practitioner doctor physician looking in distance, considering difficult medical problem solution or illness treatment, working on computer in clinic office.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Ramsay Health Care Ltd (ASX: RHC) shares are in the green on Friday despite news of a credit rating downgrade from the Fitch Ratings agency.

Ramsay shares are currently trading for $51.66, up 0.27% on Friday.

The company released a statement regarding the rating agency's downgrade today.

Let's take a look.

Ramsay shares still rising despite ratings downgrade

Fitch downgraded the investment grade credit rating ascribed to Ramsay's Funding Group from BBB/Negative to BBB-/Stable.

The Funding Group refers to Ramsay Health Care Limited and all subsidiaries, excluding Ramsay Santé.

Ramsay Health Care said:

The change in rating is not expected to impact Ramsay's ability to access funding and liquidity in the
future.

The financial impact of this change in rating on the Company's $1.5bn Sustainability Linked
Loan is a 10bp increase in interest costs.

Ramsay reconfirms that it expects its FY24 net interest expense (including AASB 16 lease costs) to be in the range of $570-600m2.

As of 30 June, Ramsay's leverage under its banking covenants was 3.2×3, which is below the covenant threshold of 4x. Ramsay says it is aiming to reduce its leverage below 2.5x.

Ramsay's interest coverage ratio was 7.35x, which is well above the banking covenant of greater than 3x.

Proposed sale of Sime Darby

Ramsay and its joint venture partner, Sime Darby Berhad are actively exploring selling their Asia-based business, Ramsay Sime Darby Health Care.

Ramsay announced this decision on 28 June, saying:

The decision has been reached following the receipt of significant inbound interest in RSD at values that are in shareholders' interests to explore, noting that there is no certainty that a sale process will result in a completed transaction.

Investors appeared supportive of the idea with Ramsay shares ascending 4.77% on the day of the news.

Since then, Ramsay says they have received "a number of non-binding indicative offers".

The company added: "A select number of parties are now in a phase 2 due diligence process expected to conclude towards the end of October".

The funds from a sale would be used to pay down debt.

Ramsay expects to announce the outcome of its deliberations before its annual general meeting (AGM).

No date for the AGM has been set as yet.

Recent history of Ramsay shares

The Ramsay Health Care share price is down 20% in the year to date.

By comparison, the S&P/ASX 200 Health Care Index (ASX: XHJ) is down 3% over the same period.

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A male doctor wearing a white doctor's coat shrugs and holds his hands up to indicate the unimpressive CSL share price as a result of OOVID-19
Share Market News

Here's why you might have just bought Healius shares

Two of the most popular super funds just loaded up on this healthcare stock.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Here's why this ASX 200 healthcare stock is roaring 13% higher on Wednesday

This healthcare company is outperforming every other stock within the ASX 200 today.

Read more »

A young woman sits at her desk in deep contemplation with her hand to her chin while seriously considering information she is reading on her laptop
Opinions

Could CSL stock be a millionaire-maker at $261

Does the exceptional biotech company still harness the power to make an investment today worth a million in the future?

Read more »

Two happy scientists analysing test results in a lab
Healthcare Shares

Why are Mesoblast shares charging 5% higher today?

This beaten down biotech is having a strong session. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Healius share price rallies amid corporate reset

An outgoing chair and a revitalised balance sheet. Healius is undergoing a makeover.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Imugene share price jumps 32% on FDA news

Here's why this biotech is having a strong start to the session.

Read more »

A medical specialist holds a red heart connected via technology and artificial intelligence (AI)
Healthcare Shares

Broker tips big gains and yields from NIB shares

Goldman Sachs is saying good things about this health insurance provider.

Read more »

A man with grahpics of robot arms, indicating a share price movement in ASX robotics and tech companies
Healthcare Shares

Up 784% in 5 years, why this ASX 200 healthcare share has a 'clear pathway' for growth in 2024

The ASX 200 stock has been a standout performer within the healthcare sector.

Read more »